Market Tracker

05/22 4:40am ET

SPDR S&P Pharmaceuticals ETF (XPH)

69.53
Data as of May 21
 +0.50 / +0.72%
Today’s Change
53.20
Today|||52-Week Range
69.84
+24.36%
Year-to-Date

Investment Objective

The investment seeks to provide investment results that, before fees and expenses, correspond to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. The fund employs a replication strategy in seeking to track the performance of the S&P Pharmaceuticals Select Industry Index. It generally invests substantially all, but at least 80%, of total assets in the securities comprising the index. The fund may invest in equity securities that are not included in the index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. It is non-diversified.

No recent news for SPDR S&P Pharmaceuticals ETF.

Performance

1 month+7.68% 3 years+22.22%
3 months+14.48% 5 years+18.93%
1 year+27.33% Since inception+13.61%
Data through 05/22/2013

Quote Details

Previous close$69.03
Open day’s range-- – --
Net asset value (NAV)69.53 (05/21/2013)
Daily volume27,691
Average volume (3 months)29,755
Data as of 4:00pm ET, 05/21/2013

Peer Comparisonvs. Health ETFs

 XPHCategory
Performance 5-yr return+18.93%+13.03%
Expense Gross exp ratio0.35%0.47%
Risk 5 year sharpe ratio1.000.75
Net assets$389.8M$776.1M
Average market cap$8.7B$19.4B
Average P/E21.321.6
Dividend / Share--0.22%

Competitors

VHT Vanguard Health Care ETF
XLV Health Care Select Sector SPDR Fund
IXJ iShares S&P Global Healthcare Index Fund

Holdings

Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ABBV AbbVie Inc4.94%
ACT Actavis Inc4.83%
ENDP Endo Health Solutions Inc4.72%
VVUS Vivus4.55%
HSP Hospira, Inc.4.40%
MRK Merck & Co Inc4.38%
JNJ Johnson & Johnson4.36%
WCRX Warner Chilcott PLC Class A4.26%
BMY Bristol-Myers Squibb Company4.25%
SLXP Salix Pharmaceuticals, Ltd.4.23%